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presence/absence of hypertension, diabetes, cardiovascular 
complications, history of stroke, history of cancer, and age/
activity level (elderly/inactive or young/active).
Results At each time point, more than three quarters of 
physicians responded that results from the TREAT study, in 
patients not on dialysis, have influenced their use of eryth-
ropoiesis-stimulating agents in patients on haemodialysis. 
At T1, there was a clear difference in physician-reported 
(theoretical) target Hb levels for patients across the dif-
ferent risk groups, but there was no difference in patients’ 
actual Hb levels across the risk groups. A similar disparity 
was noted at T2.
Conclusions Physicians’ theoretical attitudes to anae-
mia management in patients on haemodialysis appear to 
have been influenced by the results of the TREAT study, 
which involved patients not on dialysis. Physicians claim 
to use risk-based target Hb levels to guide renal anaemia 
care. However, there is discrepancy between these declared 
risk-based target Hb levels and actual target Hb levels for 
patients with variable risk factors.
Keywords Anaemia · Biosimilar epoetin alfa · 
Congruence · Guidelines · Haemodialysis · Hb targets
Introduction
Anaemia is a common complication of chronic kidney dis-
ease (CKD), particularly among patients with stage 5 CKD 
who require renal replacement therapy [1]. Evidence-based 
guidelines recommend that the target haemoglobin (Hb) 
level to be achieved in patients with CKD by treatment 
with erythropoiesis-stimulating agents (ESAs) should be 
personalised based on an individual patient’s risk factors 
and risk–benefit analysis [2, 3].
Abstract 
Purpose Data from an ongoing European pharmacoepi-
demiological study (MONITOR-CKD5) were used to 
examine congruence between physician-reported risk-
based individualisation of target haemoglobin (Hb) and the 
actual Hb targets set by these physicians for their patients, 
as well as actual Hb levels in their patients.
Methods Physician investigators participating in the study 
completed a questionnaire about their anaemia practice 
patterns and attitudes post-TREAT at the start of the study 
(T1) and in summer 2013 (T2). These data were compared 
with the Hb targets identified at baseline for actual patients 
(n = 1197) enrolled in the study. Risk groups included 
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The TREAT study, in patients with type 2 diabetes, 
CKD stage 3/4 (i.e. not receiving haemodialysis), and anae-
mia, randomised more than 4000 patients to one of two 
treatment arms: darbepoetin alfa to achieve a Hb level of 
approximately 13 g/dL or placebo, with rescue darbepoe-
tin alfa when the Hb level was <9.0 g/dL [4]. The primary 
end points were the composite outcomes of death or a car-
diovascular event and of death or end-stage renal disease. 
Treatment with darbepoetin alfa did not reduce the risk of 
either of the two primary composite outcomes [4]. How-
ever, pre-specified secondary analyses, although possibly 
underpowered [5], identified concerns related to the use of 
ESAs. Treatment with darbepoetin alfa was associated with 
a higher risk of cancer death among patients with a history 
of cancer at baseline, as well as an increased risk of fatal 
or non-fatal stroke (which appeared to be higher in patients 
with a history of stroke at baseline [4, 6]).
These findings understandably caused concern among 
the medical community and caused regulatory bodies in 
the USA (Food and Drug Administration) and Europe 
(European Medicines Agency) to recommend a more cau-
tious approach to ESA use in the whole CKD population. 
Conversely, some scientists have questioned the validity of 
extrapolating data from TREAT and other studies in CKD 
stage 3/4 patients to the haemodialysis population [5, 7].
In light of the reaction to TREAT, as well as the more 
recent changes in the European labels for ESAs that set tar-
get Hb levels in the 10–12 g/dL range, we used data from 
the ongoing MONITOR-CKD5 study [8] to examine the 
congruence between physician-reported risk-based indi-
vidualisation of target Hb and the actual Hb targets set by 
these physicians for their patients, as well as actual Hb lev-
els obtained in their patients. We also report data from this 
study on Hb outcomes and dosing stability with biosimilar 
epoetin alfa (Binocrit®, Sandoz).
Methods
MONITOR-CKD5 is a European pharmacoepidemio-
logical study examining the multi-level determinants, pre-
dictors, and clinical outcomes of biosimilar epoetin alfa 
(Binocrit®) in haemodialysis patients. Full details of the 
study design have been reported previously [8]. Included 
patients are male or female adults on chronic haemodialy-
sis due to end-stage renal disease (CKD stage 5), diagnosed 
with renal anaemia, and converted to anaemia management 
with biosimilar epoetin alfa.
For the present analysis, physician investigators partici-
pating in the MONITOR-CKD5 study were queried about 
their anaemia practice patterns and attitudes post-TREAT. 
The questionnaire was completed at the start of the study 
as centres were opened and patient enrolment began (T1, 
starting in 2009), and (per later decision) repeated with 
some modifications in summer 2013 (T2). The second time 
point was chosen to allow for the diffusion of the TREAT 
results and to capture the impact of its secondary findings. 
In particular, information was gathered on their target Hb 
values for various risk groups of patients receiving haemo-
dialysis (hypothetical targets). These data were compared 
with the Hb targets identified at baseline for actual patients 
(n = 1197) enrolled in the study (patient targets). Hb tar-
gets were categorised as <10, 10–10.9, 11–11.9 and ≥12 g/
dL. Risk groups included presence/absence of hypertension 
(HTN), diabetes, cardiovascular complications, history of 
stroke, history of cancer, and age/activity level (elderly/
inactive or young/active). For Hb outcomes and dosing 
stability, data were evaluated based on the first 18 monthly 
visits (n = 2087 at baseline).
Results
Anaemia management and practice patterns
Centre and physician characteristics are shown in Table 1. 
Although fewer centres/physicians participated at T2, 
the characteristics were similar to those who participated 
at T1. The different guidelines followed by those physi-
cians questioned are shown in Fig. 1. There was a drop 
in the proportion of centres adopting the Kidney Disease 
Outcomes Quality Initiative and European Renal Best 
Practice guidelines between T1 and T2. At T2, ~80 % of 
centres had adopted the updated Kidney Disease-Improv-
ing Global Outcomes (KDIGO) guidelines (these had not 
been published at T1). There was a statistically significant 
shift in the anaemia practice guidelines adopted by centres 
from T1 to T2 (p < 0.001). At T2, the KDIGO 2007 posi-
tion statement and 2012 guidelines prevailed, and there was 
Table 1  Physician and centre characteristics
T1 T2
Centre
 N 109 74
 Academic (%) 13.3 15.9
 Academic affiliated (%) 11.4 12.1
 Non-academic (%) 75.3 72.0
Mean (±SD) number of  
patients dialysed per week
101.0 (±59.9) 106.8 (±64.8)
Physician
 N 166 97
 Male/female (%) 69.7/30.3 66.3/33.7
 Mean (±SD) age (years) 49.4 (±9.0) 49.7 (±8.2)
 Mean (±SD) years of practice 23.6 (±9.1) 24.2 (±8.8)
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a continued modest adoption of the European Renal Best 
Practice guidelines. At both T1 and T2, most centres relied 
on more than one guideline.
At each time point, more than three quarters of phy-
sicians responded that results from the TREAT study, 
in patients not on dialysis, have influenced their use of 
ESAs in patients on haemodialysis (T1, 77 %; T2, 78 %). 
There was no difference in the theoretical Hb threshold 
for ESA use (10 g/dL at both time points) and blood 
transfusions (7.4 g/dL at T1, 7.5 g/dL at T2). There was 
a lower ‘universal’ target Hb at T2 compared with T1 
(40 % reported a target of <11.0 g/dL at T2, compared 
with 27 % at T1).
Figure 2 depicts for T1 (panel A) and T2 (panel B) the 
physician-reported (theoretical) target Hb and patients’ Hb 
levels, stratified by risk groups. Presented for T1 are the 
theoretical target Hb ranges and actual Hb levels at base-
line, at 18 months, and across all visits (with risk factors 
listed in descending order of the proportion of physicians 
reporting a theoretical Hb target ≤10.9 g/dL for a given 
risk factor). As the upper graph in panel A shows, propor-
tionately more physicians endorsed theoretical Hb targets 
≤10.9 g/dL for the six risk groups of stroke, elderly, can-
cer, cardiovascular disease, HTN, and diabetes. In com-
parison, relatively more physicians reported using theo-
retical Hb targets ≥11 g/dL in patients without these risk 
factors. In contrast, patients’ actual Hb levels at baseline, 
at 18 months, and across all visits were similar across risk 
groups. Consistently across these three data points, at least 
50 % of patients had Hb levels of 11 g/dL or more, and 
(with a few exceptions) at least 20 % of patients had Hb 
levels 12 g/dL or higher.
Figure 2b illustrates theoretical upper Hb targets at 
T2 versus patients’ baseline upper target Hb, by risk fac-
tor. Between 29.0 % (for the risk factor history of stroke) 
and 85.5 % (for the risk factor age <50 years) of physi-
cians endorsed theoretical upper Hb targets of 12 g/dL or 
more. In contrast, the second graph in panel B shows that 
for about 80 % of patients a Hb level below 12 g/dL was 
specified as the target Hb to be pursued and, conversely, 
that only for about 20 % of patients a Hb level ≥12 g/dL 
was envisioned.
When questioned specifically on their anaemia man-
agement approach in patients with a history of cancer (of 
specific interest following the TREAT study), 47 and 49 % 
of respondents at T1 claimed to consider time in remission 
and cancer burden when setting target Hb and ESA dose, 
respectively; 32 % answered that cancer history was not 
relevant. At T2, time in remission and cancer burden was 
considered relevant by 45 and 62 % of respondents, respec-
tively; 25 % considered cancer history as not relevant. Phy-
sicians were also questioned about theoretical Hb targets 
and ESA doses in patients with a history of cancer, com-
pared with those with no history of cancer (Fig. 3). For 
Hb, at T1, 25 % had a lower theoretical target, 65 % had 
the same target, and 10 % had a higher Hb target; at T2, 
Fig. 1  Centre adoption of clinical practice guidelines for anaemia management in patients with CKD (categories not mutually exclusive). 
KDIGO Kidney Disease-Improving Global Outcomes, KDOQI Kidney Disease Outcomes Quality Initiative
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15 % had a lower Hb target and 85 % had the same target. 
For ESA dose, at T1, 31 % had a lower theoretical dose, 
40 % had the same dose, and 29 % had a higher dose; at 
T2, 22 % had a lower theoretical dose, 74 % had the same 
dose, and only 4 % had a higher ESA dose. When actual 
Hb targets and ESA doses used were assessed for those 
with and without a history of cancer, no differences were 
found between the two groups (Fig. 3) (all p = ns).
At T1, 47 % of physicians reported that they did have 
an upper limit for weekly ESA dose that they would not 
exceed. At T2, this proportion increased to 74 %. The 
distribution of these maximum weekly doses is shown in 
Fig. 2  a Theoretical target Hb range at T1 and actual Hb levels at baseline, at 18 months, and across all visits. b Theoretical upper target Hb at 
T2 and actual upper target Hb at baseline
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Fig. 4. At T2, more than 40 % of respondents identified an 
upper limit of 30,000 IU/week or more.
The survey also included questions on iron manage-
ment practices. At T1, 81 % responded that they did 
have an upper target for serum ferritin that they would 
not intentionally exceed. Among these physicians, this 
upper target was 500 µg/L for 52 %, 750 µg/L for 30 %, 
and ≥1000 µg/L for 18 %. A shift towards a higher upper 
target for serum ferritin was noted at T2. At T2, 96 % of 
physicians replied that they had an upper serum ferritin 
target; among this group, the upper target was 500 µg/L 
for 29 %, 750 µg/L for 38 %, and ≥1000 µg/L for 33 %. 
Actual iron status by risk group is shown in Fig. 5. No sig-
nificant differences in iron store by risk group pairs (e.g. 
between those with HTN and those without HTN) were 
found, except for diabetes; diabetics had a significantly 
lower rate of adequate iron stores than non-diabetics (65.5 
vs. 75.8 %, χ2 = 8.24, p = 0.0162). Iron supplementation 
by risk group is also shown (Fig. 5); no significant differ-
ences in risk group pairs were found.
Iron status and supplementation were also explored by 
region (data not shown). Patients in Eastern Europe (EE) 
had significantly higher rates of adequate iron compared 
with patients in Western Europe (WE) (80.1 vs. 69.8 %, 
χ2 = 36.87, p < 0.0001), yet there was no significant 
difference in iron supplementation rates (62.7 vs. 67.8 %, 
χ2 = 3.46, p = 0.0630).
Dosing, Hb, and safety outcomes
The majority of patients (82 %) were already receiving 
ESA therapy on study entry. Mean (SD) weekly dose of 
biosimilar epoetin alfa was 7532 (5342) IU, and mean 
(SD) Hb at baseline was 11.15 (1.17) g/dL. Dose of 
biosimilar epoetin alfa and Hb level over 18 months by 
region are illustrated in Fig. 6. Across all visits, patients 
in EE had significantly lower doses than patients in WE 
controlling for age and comorbidities (β = −0.2834, 
p < 0.0001; note that dose has been logarithmised, so the 
estimate represents percentage difference); and, while 
both EE and WE doses varied significantly over time 
(β = −0.0127, p < 0.0001 and β = −0.0034, p = 0.0370, 
respectively), the difference in trajectory was signifi-
cantly different (β = −0.0093, p = 0.0042) with EE 
having a clear decline (from 6300 to 5500 IU/wk), while 
WE remained between 7900 and 8300 IU/wk but with 
month-to-month variability. Hb was also significantly dif-
ferent between regions controlling for age and number 
of comorbidities (β = −0.2114 g/dL, p < 0.0001) and 
with significantly different trajectories (β = −0.0165, 
Fig. 2  continued
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p = 0.0002): EE had small but significant Hb decline 
(β = −0.0166, p < 0.0001), while WE had no significant 
change (β = −0.0001, p = 0.9618). At enrolment, 25 % 
of patients had experienced a prior thromboembolic event 
(TEE). During follow-up, 9.4 % of patients had a TEE, of 
which the majority were shunt thrombosis.
Discussion
Our findings show that physicians’ attitudes towards 
anaemia management in haemodialysis patients have 
been influenced, at least in theory, by the findings of the 
TREAT study, conducted in patients with CKD not on 
Fig. 3  Anaemia management approach and practices in patients with and without a history of cancer. a Hb targets. b ESA dose. ESA erythro-
poiesis-stimulating agent, Hb haemoglobin, Hx history
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haemodialysis. However, our data also demonstrate a dis-
crepancy between these theoretical TREAT-influenced atti-
tudes and actual practice patterns in terms of risk-based 
individualisation of target Hb levels and ESA dosing; while 
respondents claimed to use individualised target Hb lev-
els for various risk groups, this is not reflected in patients’ 
actual Hb levels. The discrepancy at T2 (between theo-
retical upper Hb targets for specific risk groups and actual 
upper Hb targets at baseline) is particularly interesting 
given the apparent widespread adoption of KDIGO guide-
lines at this time point, which include probably the clear-
est recommendations yet on differential anaemia manage-
ment. Thus while TREAT may have suggested the need 
for individualised Hb targets, which are also advocated in 
clinical practice guidelines, the clinical reality may be one 
of the ‘universally conservative’ Hb targets without risk 
stratification.
There are a number of possible explanations for the dis-
crepancies between theoretical anaemia management and 
actual practice patterns. One is social desirability bias [9] 
which in the context of the current study might result in 
physicians giving the answers that they think are expected. 
Another possibility is that physicians are aware of the guide-
line recommendations but either have not translated them 
into their daily clinical practice or are outright sceptical of 
them. Further, as the European data from TREAT are differ-
ent from the US data [4–10], European nephrologists may 
be doubtful of the TREAT findings and their generalisability 
Fig. 4  Distribution of maximum weekly ESA doses among physi-
cians who responded that they do have an upper limit that should not 
be exceeded (doses are IU except where noted). ESA erythropoiesis-
stimulating agent
Fig. 5  Iron status and iron supplementation by risk group
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to Europe. Time constraints may be another reason for the 
discrepancy between theory and practice; individualising 
treatment is time intensive, and it is easier/quicker to treat 
all patients according to established centre protocols. Reim-
bursement issues and increased use of bundling of care for 
haemodialysis patients may also contribute to lack of indi-
vidualised anaemia management in actual practice. Another 
possible contributory factor is the influence of physicians’ 
training; for example, there are some data to suggest that 
US-trained doctors are more likely to be prepared to use 
higher ESA doses than their European counterparts [11].
The TREAT study raised particular concerns about use 
of ESAs in CKD patients with a history of cancer or stroke 
[4, 6]. The discrepancy in the present study between theo-
retical attitudes and actual practice patterns among these 
patient groups is noteworthy, given that more than 75 % 
of participating physicians indicated that results from the 
TREAT study (in patients not on dialysis) have influenced 
their use of ESAs in patients on haemodialysis, yet this is 
not evident in the actual Hb data.
Our data suggest a shift (at least in theory) to more 
aggressive use of iron supplementation in the manage-
ment of anaemia in haemodialysis patients, as indicated 
by the increase at T2 in the proportion of physicians with 
a higher upper target for serum ferritin. This is consistent 
with reports from the Dialysis Outcomes and Practice Pat-
terns Study, in which increasing use of intravenous iron and 
a rise in serum ferritin levels have been recorded [12, 13]. 
The increased use of iron to manage anaemia is likely to 
be reflective of more widespread use of bundling of care 
for haemodialysis patients, as well as a desire among phy-
sicians to limit the use of ESAs.
Significant regional variation in biosimilar epoetin alfa 
dosing was found; however, this did not translate into clini-
cally significant differences in achieved Hb. While EE had 
approximately 28 % lower doses over the 18-month obser-
vation period, Hb was only 0.2 g/dL lower. Interestingly, 
patients in EE had significantly better iron stores than 
patients in WE but with no difference in supplementation 
rates. Nutritional, environmental, and/or genetic factors 
may contribute to this finding.
Data so far from the MONITOR-CKD5 study show that 
biosimilar epoetin alfa maintains stable longitudinal Hb 
outcomes, reflecting the same patterns as known with the 
originator epoetin alfa product. The data from MONITOR-
CKD5 on Hb and dosing outcomes are also consistent with 
those from phase III and phase IV studies with this biosim-
ilar epoetin alfa [14, 15].
Fig. 6  Mean Hb and biosimilar epoetin alfa dose by region
845Int Urol Nephrol (2015) 47:837–845 
1 3
Conclusions
Physician investigators in the MONITOR-CKD5 study 
assert that their attitudes related to the use of ESAs in 
patients on haemodialysis have been influenced (at least in 
theory) by the results of the TREAT study, which involved 
patients not on dialysis. Physicians claim to use risk-based 
target Hb levels to guide renal anaemia care. However, 
there is discrepancy between these declared risk-based tar-
get Hb levels and actual target Hb levels for patients with 
variable risk factors. Further research is required to deter-
mine why the gap exists between hypothetical and actual 
target Hb levels.
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